Skip to main content
main-content

11.07.2017 | Onkologie | Onlineartikel

Reducing the danger that arises from the CNS as a site of progression

Brain metastases and leptomeningeal disease represent major clinical challenges in the management of patients with NSCLC. They are generally associated with poor prognosis, and their treatment is difficult due to the paucity of effective therapeutic options. Moreover, patients with CNS lesions are frequently excluded from clinical trials. Progress in this area is therefore slow, and more treatments are urgently needed.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten